Cart
sales@molnova.com
JNJ16259685
CAS No. 409345-29-5
JNJ16259685( .TN.T 16259685 )
Catalog No. M24372 CAS No. 409345-29-5
JNJ16259685 is a selective mGluR1 antagonist, and inhibits the synaptic activation of mGluR1 in a concentration-dependent manner with IC50 of 19 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 97 | In Stock |
|
| 2MG | 56 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 293 | In Stock |
|
| 50MG | 439 | In Stock |
|
| 100MG | 641 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ16259685
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ16259685 is a selective mGluR1 antagonist, and inhibits the synaptic activation of mGluR1 in a concentration-dependent manner with IC50 of 19 nM.
-
DescriptionJNJ16259685 is a selective mGluR1 antagonist, and inhibits the synaptic activation of mGluR1 in a concentration-dependent manner with IC50 of 19 nM.
-
In VitroJNJ16259685 potently and completely inhibits the glutamate (30 μM)-induced increase in intracellular Ca2+?concentrations at the rat mGlu1a receptor with an IC50?value of 3.24±1.00 nM. IC50?values for CPCCOEt and BAY 36-7620 are 17.8±10.3 μM and 161±38 nM, respectively. The potency of JNJ16259685 in blocking glutamate (30 μM)-induced Ca2+ mobilization at the human mGlu1a receptor is 1.21±0.53 nM (IC50?n=3). JNJ16259685 inhibits the glutamate (3 μM)-induced rise in intracellular Ca2+?concentrations at the rat mGlu5a receptor with an IC50?value of 1.31±0.39 μM (n=4). JNJ16259685 blocks glutamate (3 μM)-induced Ca2+?mobilization at the human mGlu5 receptor with an IC50?of 28.3±11.7 μM (n=4). JNJ16259685 does not exhibit agonist activity at any of the group I mGlu receptors.
-
In VivoJNJ16259685 (0.125, 0.25, 0.5, 1, 2, 4 and 8?mg/kg, i.p) significantly reduces the time spent in digging behaviours (0.25-8 mg/kg), threat (all doses) and attack, in comparison with vehicle group. JNJ16259685 (30 mg/kg) produces very minimal effects on locomotor activity. JNJ16259685 dramatically reduces rearing behavior, exploration of a novel environment and lever pressing for a food reward (rat: 0.3 mg/kg; mouse: 1 mg/kg). Subcutaneously administered JNJ16259685 (30 mg/kg) has no effect on reflexive startle responses to loud auditory stimuli or foot shock in mice. JNJ16259685 exhibits high potencies in occupying central mGlu1 receptors in the rat cerebellum and thalamus (ED50=0.040 and 0.014 mg/kg, respectively).
-
Synonyms.TN.T 16259685
-
PathwayNeuroscience
-
TargetGluR
-
RecptormGluR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number409345-29-5
-
Formula Weight325.4
-
Molecular FormulaC20H23NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 100 mg/mL (307.31 mM)
-
SMILESO=C(C1=CC=C2N=C3C(CCCO3)=CC2=C1)[C@H]4CC[C@@H](OC)CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
FPTQ B
FPTQ is a highly effective antagonist of mGluR 1, displaying IC50 values of 6 nM and 1.4 nM for human and mouse mGluR1 respectively . In addition to its robust inhibitory properties, FPTQ exhibits notable antioxidant and anti-inflammatory effects in both in vitro and in vivo settings .
-
S-(4-Hydroxybenzyl)g...
L-γ-Glutamyl-S-[(4-hydroxyphenyl)methyl] was isolated as the major principle responsible for the inhibition of the in vitro binding of kainic acid to brain glutamate receptors by water extracts of the plant Gastrodia elata.
-
(S)-4CPG
(S)-4CPG ((S)-4-Carboxyphenylglycine) is a competitive mGlu1 receptor antagonist that attenuates nociceptive hypersensitivity and nociceptive abnormalities associated with sciatic nerve constriction injuries in rats, and may be used in the study of neurological disorders.
